A multi-center study of high dose Aldesleukin (Proleukin® (HD IL-2) + Vemurafenib Zelboraf® ) therapy in patients with BRAFV600 mutation positive metastatic melanoma (proclivity 01)
Joseph Clark, Lawrence Flaherty, Marc Ernstoff, Henry Koon, Mohammed Milhem, Gerald Militello, Sanjiv Agarwala, Brendan Curti, Lee Cranmer, Christopher D Lao, Theodore F Logan, Jose Lutzky, Venkatesh Rudrapatna, Gregory Daniels, Bret Taback, Sandra Aung, James Lowder, David Lawson
Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P77; DOI: 10.1186/2051-1426-2-S3-P77